Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals reported a net loss of $(1,721,528) for the three months ended June 30, 2026, and $(2,712,475) for the six months. The company's cash balance decreased to $5.17 million by June 30, 2026, from $7.29 million at the end of 2025, with $2.79 million used in operations during the first half of 2026. Management issued a going concern warning, indicating insufficient cash to fund operations for the next 12 months. Additionally, Telomir completed its merger with related party TELI Pharmaceuticals, Inc. on April 22, 2026, acquiring global rights to Telomir-Zn.

Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data for Telomir-Zn in the Journal of Oncology Research and Therapy. The study demonstrates Telomir-Zn's ability to suppress tumor growth in prostate and triple-negative breast cancer (TNBC) models by selectively modulating intracellular iron and copper, inhibiting KDM enzymes, and reactivating tumor-suppressor genes. These findings provide strong scientific foundation for advancing Telomir-Zn to a planned Phase 1/2 clinical trial in TNBC, addressing a significant unmet need in oncology.

Telomir Pharmaceuticals announced the publication of a peer-reviewed preclinical study in the Journal of Oncology Research and Therapy. The study demonstrated that Telomir-Zn suppresses tumor growth in prostate and triple-negative breast cancer (TNBC) models by inhibiting histone demethylases (KDMs) through intracellular iron depletion. Key findings include the reactivation of silenced tumor-suppressor genes, significant reduction in metastatic dissemination, and synergistic effects when combined with paclitaxel. These preclinical results provide a scientific foundation for advancing Telomir-Zn towards a planned Phase 1/2 clinical trial in TNBC.

Telomir Pharmaceuticals, Inc. announced its Annual Meeting of Shareholders will be held virtually on September 11, 2026. Shareholders will vote on the election of four directors, the ratification of Salberg & Company, P.A. as the independent registered public accounting firm for fiscal year 2026, and a proposal to adjourn the meeting if necessary. The Board of Directors recommends voting "FOR" all proposals.

Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data for Telomir-Zn in Biomedicine & Pharmacotherapy. The study demonstrated that Telomir-Zn restored insulin sensitivity and significantly improved glucose homeostasis in a diet-induced zebrafish model of Type 2 diabetes. This publication provides further validation of Telomir-Zn's mechanism of action through modulation of intracellular metal homeostasis, supporting its broader potential and the scientific foundation for its lead clinical program in triple-negative breast cancer, which recently received FDA IND clearance.

Telomir Pharmaceuticals, Inc. announced a change in its Chief Financial Officer position. Alan Weichselbaum ceased serving as CFO effective June 6, 2026, with his departure not stemming from any disagreements. The company's board of directors appointed Andriy Mushak as the new fractional Chief Financial Officer, effective the same date. Mr. Mushak, a CPA with over 20 years of experience in SEC reporting and accounting, will provide his services through LMAM Consulting Group, LLC, for a monthly fee of $6,000.

Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data for Telomir-Zn in the journal Advances in Redox Research. The study demonstrated dose-dependent survival improvement and multiple endpoint benefits in a zebrafish model of Wilson's disease, including reduced oxidative stress, hepatic copper accumulation, and improved liver biomarkers. These findings support the biological activity of Telomir-Zn and its broader mechanistic profile, as the company advances its lead program in Triple-Negative Breast Cancer.

Telomir Pharmaceuticals completed its merger with TELI Pharmaceuticals, Inc. on April 22, 2026, issuing 34,389,710 restricted shares to former TELI stockholders. The company also announced FDA IND clearance for Telomir-Zn to initiate a clinical trial for triple-negative breast cancer. For the three months ended March 31, 2026, Telomir reported a reduced net loss of $0.99 million, down from $2.18 million year-over-year, and a net loss per share of $0.03. However, the company faces substantial doubt about its ability to continue as a going concern due to insufficient cash to support operations for the next 12 months.

Telomir Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Telomir-Zn. This lead product candidate is intended for the treatment of patients with advanced or metastatic triple-negative breast cancer. The company plans to initiate a first-in-human Phase 1/2 clinical trial in the first half of 2026, which is expected to enroll approximately 76 patients. The study will evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy, with objective response rate as the primary endpoint for the Phase 2 portion.

Telomir Pharmaceuticals, Inc. completed its acquisition of TELI Pharmaceuticals, Inc. on April 22, 2026, following shareholder approval on March 23, 2026. The transaction involved issuing 34,389,710 restricted shares of Telomir's common stock to TELI's former shareholders. This acquisition consolidates the global rights of Telomir-1 (Telomir-Zn) under Telomir, eliminating prior geographic fragmentation and granting full control over its development and commercialization. Additionally, Bayshore Trust contributed $1 million at closing and holds an option to invest up to $4 million more upon the achievement of specific clinical milestones for Telomir-1.